These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 6473479)

  • 1. [Effect of 4 formulation factors on the release of indomethacin from inert matrices with a Eudragit base].
    Gueurten D
    Pharm Acta Helv; 1984; 59(7):200-4. PubMed ID: 6473479
    [No Abstract]   [Full Text] [Related]  

  • 2. Dissolution behaviour of sustained release formulations of indomethacin with Eudragit RS.
    Khanfar MS; Salem MS; Najib NM; Pillai GK
    Acta Pharm Hung; 1997 Nov; 67(6):235-9. PubMed ID: 9423295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sensitivity of cationic polymer Eudragit RL to electrolytes and its effect on drug release from Eudragit RL matrix].
    Fu C; Zhao L; Jiang X
    Yao Xue Xue Bao; 1998 Jul; 33(7):538-43. PubMed ID: 12016889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eudragit matrices for sustained release of ketorolac tromethamine: formulation and kinetics of release.
    Ruckmani K; Muneera MS; Vijaya R
    Boll Chim Farm; 2000; 139(5):205-8. PubMed ID: 11213438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery.
    Akhgari A; Afrasiabi Garekani H; Sadeghi F; Azimaie M
    Int J Pharm; 2005 Nov; 305(1-2):22-30. PubMed ID: 16236475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Permeability and swelling studies on free films containing inulin in combination with different polymethacrylates aimed for colonic drug delivery.
    Akhgari A; Farahmand F; Afrasiabi Garekani H; Sadeghi F; Vandamme TF
    Eur J Pharm Sci; 2006 Jul; 28(4):307-14. PubMed ID: 16713201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The attempts of retarding the release of nitroglycerin from granules.
    Stozek T
    Pol J Pharmacol Pharm; 1977; 29(4):425-9. PubMed ID: 410011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of time-dependent and pH-dependent polymethacrylates as a single coating formulation for colonic delivery of indomethacin pellets.
    Akhgari A; Sadeghi F; Garekani HA
    Int J Pharm; 2006 Aug; 320(1-2):137-42. PubMed ID: 16782290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets.
    Ceballos A; Cirri M; Maestrelli F; Corti G; Mura P
    Farmaco; 2005; 60(11-12):913-8. PubMed ID: 16129436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-controlled pulse-drug release from dry-coated wax matrix tablets for colon drug delivery.
    Peerapattana J; Otsuka K; Otsuka M
    Biomed Mater Eng; 2004; 14(3):293-301. PubMed ID: 15299241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application of aqueous Eudragit dispersions to the preparation of controlled release oral antihistamine dosage forms].
    Dévay A; Rácz I
    Acta Pharm Hung; 1988 Jul; 58(4):166-72. PubMed ID: 2906204
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55.
    Sauer D; Zheng W; Coots LB; McGinity JW
    Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic evaluation of the effect of thermal-treating on Eudragit RS matrices.
    Azarmi S; Ghaffari F; Löbenberg R; Nokhodchi A
    Farmaco; 2005; 60(11-12):925-30. PubMed ID: 16223498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetic tests with delayed-absorption Halidor-Eudragit L complex in dogs].
    Elekes I; Auer P; Pátfalusi M; Orbán E
    Acta Pharm Hung; 1981 Mar; 51(2):66-9. PubMed ID: 7270207
    [No Abstract]   [Full Text] [Related]  

  • 15. [Formulation of sustained release tablets. I. Inert matrices].
    Salomen JL; Doelker E
    Pharm Acta Helv; 1980; 55(7):174-82. PubMed ID: 7413682
    [No Abstract]   [Full Text] [Related]  

  • 16. Citric acid as a solid-state plasticizer for Eudragit RS PO.
    Schilling SU; Shah NH; Malick AW; Infeld MH; McGinity JW
    J Pharm Pharmacol; 2007 Nov; 59(11):1493-500. PubMed ID: 17976259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fabrication and coating of microgranules of acetylsalicylic acid: use of eudragit L30D].
    Dechesne JP
    J Pharm Belg; 1987; 42(2):85-94. PubMed ID: 3612481
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of the deformation behavior of binary systems of methacrylic acid copolymers and hydroxypropyl methylcellulose using a compaction simulator.
    Tatavarti AS; Muller FX; Hoag SW
    Int J Pharm; 2008 Feb; 348(1-2):46-53. PubMed ID: 17714895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Studies on heart-protecting musk pH-dependent gradient-release pellets].
    Song HT; Guo T; Zhang RH; Ma Y; Li X; Bi KS
    Yao Xue Xue Bao; 2002 Oct; 37(10):812-7. PubMed ID: 12567868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naproxen-Eudragit microspheres: screening of process and formulation variables for the preparation of extended release tablets.
    Zaghloul AA; Faltinek J; Vaithiyalingam SR; Reddy IK; Khan MA
    Pharmazie; 2001 Apr; 56(4):321-4. PubMed ID: 11338673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.